SCHEMBL3750013

SCHEMBL3750013

O=C1Nc2ccc(Br)cc2/C1=C/c1cc(Br)cc(Br)c1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP1LC3B Q9GZQ8 3/20 0.69
PLK4 O00444 4/20 0.68
MEN1 O00255 2/20 0.67
KMT2A Q03164 2/20 0.67
RPS6KA3 P51812 1/20 0.60
PLK1 P53350 2/20 0.59
RET P07949 1/20 0.59
PDGFRB P09619 2/20 0.57
RAF1 P04049 3/20 0.56
PSEN1 P49768 1/20 0.56
PSEN2 P49810 1/20 0.56
LRRK2 Q5S007 1/20 0.56
APH1B Q8WW43 1/20 0.56
NCSTN Q92542 1/20 0.56
APH1A Q96BI3 1/20 0.56
PSENEN Q9NZ42 1/20 0.56
TGM2 P21980 1/20 0.56
CES1 P23141 1/20 0.56
EGFR P00533 1/20 0.56
NTRK1 P04629 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3749415 0.87 LRRK2 (0.74) RPS6KA3RETPDGFRBPSEN1PSEN2
SCHEMBL3748098 0.87 FLT3 (0.56) MAP1LC3BPLK4MEN1KMT2APLK1
SCHEMBL6857929 0.86 MEN1 (0.73) MAP1LC3BPLK4MEN1KMT2ARPS6KA3
SCHEMBL6835454 0.86 MEN1 (0.73) MAP1LC3BPLK4MEN1KMT2ARPS6KA3
SCHEMBL5774043 0.85 MAP1LC3B (0.88) MAP1LC3BPLK4MEN1KMT2APLK1
SCHEMBL5774039 0.85 MAP1LC3B (0.88) MAP1LC3BPLK4MEN1KMT2APLK1
SCHEMBL3754416 0.85 MAP1LC3B (0.88) MAP1LC3BPLK4MEN1KMT2APLK1
SCHEMBL6689356 0.85 PLK4 (0.78) MAP1LC3BPLK4MEN1KMT2APLK1
SCHEMBL3749858 0.84 RAF1 (0.72) PLK4MEN1KMT2APLK1RET
SCHEMBL13080585 0.84 RAF1 (0.72) PLK4MEN1KMT2APLK1RET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100298376-A1 USE OF NOVEL NEUROPROTECTIVE 3-SUBSTITUTED INDOLONE COMPOSITIONS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2010-11-25 US claimed
US-20090264494-A1 USE OF NEUROPROTECTIVE 3-SUBSTITUTED INDOLONE COMPOSITIONS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2009-10-22 US claimed
US-20100298376-A1 USE OF NOVEL NEUROPROTECTIVE 3-SUBSTITUTED INDOLONE COMPOSITIONS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2010-11-25 US disclosed
US-20100298376-A1 USE OF NOVEL NEUROPROTECTIVE 3-SUBSTITUTED INDOLONE COMPOSITIONS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2010-11-25 US disclosed
US-20090264494-A1 USE OF NEUROPROTECTIVE 3-SUBSTITUTED INDOLONE COMPOSITIONS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2009-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298376-A1 USE OF NOVEL NEUROPROTECTIVE 3-SUBSTITUTED INDOLONE COMPOSITIONS NLN, HTT, PARK7 MAP1LC3B 187/4885PLK4 1784/4885MEN1 3621/4885
US-20090264494-A1 USE OF NEUROPROTECTIVE 3-SUBSTITUTED INDOLONE COMPOSITIONS NLN, BDNF, HTT MAP1LC3B 76/4885PLK4 1562/4885MEN1 4547/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.